ReviewOphthalmology science
Optical Strategy Utilizing Contrast Modulation to Slow Myopia.
Review in Ophthalmology science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The Impact of Myopia Control Spectacle Lens Designs on Visual Function.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Trial
- Effect of Increased Power and Asphericity of Highly Aspherical Lenslets on Myopia Control Efficacy: A Contralateral Crossover Study.Translational vision science & technology · 2025Trial
- Clinical evaluation of MyoCare in Europe (CEME) for myopia management: One-year results.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025Trial
- Spectacle lenses for control of myopia progression in children.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Review
- Lrrn-mediated retinal ganglion cell targeting drives visual circuit assembly for brightness and contrast detection.Science advances · 2026Article
- Atropine-Loaded Contact Lens Sustained-Release Systems: A Narrative Review for the New Frontier for Myopia Management.Ophthalmology and therapy · 2026Review
- Editorial: Interventional modalities for the prevention and management of childhood myopia.Frontiers in ophthalmology · 2026Article
- Potential Ferroptosis-Related Genes and Immune Infiltration in Form-Deprivation Myopia: An Integrative Bioinformatics and in vitro Validation Study.International journal of general medicine · 2026Article
- Next-Generation Spectacle Lenses for Myopia Control: Optical Designs, Mechanisms, and Clinical Efficacy.Journal of clinical medicine · 2025Review
- Scoping Review of the Role of Accommodation and Binocular Coordination in Myopia Onset and Progression.Clinical ophthalmology (Auckland, N.Z.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new method to slow myopia progression utilizes Diffusion Optics Technology (DOT) spectacle lenses. The proposed mechanism of action for the DOT lenses is to modulate contrast across the photoreceptor cells, leading to an altered activity of the ON and OFF pathways and slowing the progression of axial elongation. This approach is different from the current optical approaches that utilize optical defocus to reduce hyperopic defocus at the peripheral retina although central vision is fully corrected to slow myopia. Initial clinical studies with the DOT lenses have demonstrated promising results with a reduction in progression of myopia. This overview summarizes the current knowledge on myopia risk factors, the evidence for involvement of contrast signaling pathways in refractive error development, and the theories and mechanisms behind DOT lens technology. It also considers the role of contrast and the paradoxical observations given the established paradigm of form deprivation in animal models. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.